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Adipose morphology is defined as the number and size distribution of adipocytes (fat cells) 13 
within adipose tissue. Adipose tissue with fewer, but larger adipocytes is termed as having a 14 
‘hypertrophic’ morphology, whereas adipose with many adipocytes, of a smaller size, is termed a 15 
‘hyperplastic’ morphology. Hypertrophic adipose morphology is positively associated with insulin 16 
resistance, diabetes and cardiovascular disease. Contrastingly, hyperplastic morphology is 17 
associated with improved metabolic parameters. These phenotypic associations suggest that 18 
adipose morphology influences risk for cardiometabolic disease. Intriguingly, monozygotic twin 19 
studies have determined that adipose morphology is in part genetically determined. Therefore, 20 
identifying the genetic regulation of adipose morphology may help predict, prevent and ameliorate 21 
insulin resistance and associated metabolic diseases. Here we review the current literature 22 
regarding adipose morphology in relation to; (i) metabolic and medical implications, (ii) methods 23 
used to assess adipose morphology, and (iii) transcriptional differences between morphologies. 24 
We further highlight three mechanisms hypothesized to promote adipocyte hypertrophy and thus 25 
regulate adipose morphology.  26 
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Adipose tissue (AT) is a morphologically unique organ that accumulates lipid in response 27 
to an organism’s energy status. During periods of caloric excess, AT sequesters circulating lipid 28 
which accumulates mainly as triacylglyceride (TAG) in cytoplasmic lipid droplets (LDs) within 29 
adipocytes (fat cells). Conversely, during periods of caloric need, AT mobilizes lipid from LDs into 30 
the circulation to act as an energy source for peripheral tissues. As such, AT functions as an 31 
energy buffer to protect an individual from adverse physiological demands. The ability to expand 32 
and contract to such extreme degrees, is unique to AT among other adult tissues. For example, 33 
in an individual whose weight increased from 70 to 150 kg, the AT mass quadrupled relative to 34 
changes in skeletal or muscle mass (Prins and O'Rahilly, 1997). Fluctuation in AT mass is largely 35 
due to changes in lipid volume and, to accommodate such dynamic variation, AT expands via 36 
increases in adipocyte size (hypertrophy) and adipocyte number (hyperplasia) and contracts via 37 
decreases in adipocyte size (hypotrophy) (Salans et al., 1973; Spalding et al., 2008). The balance 38 
between these growth and regression states establishes and maintains AT morphology: AT with 39 
fewer, but very large adipocytes is termed a hypertrophic morphology; whereas, AT with many, 40 
smaller adipocytes in termed hyperplastic (Fig. 1A). In this review, we highlight how adipose 41 
morphology is associated with metabolic and physiological derangements, and present 42 
hypotheses for how adipose morphology may be regulated.  43 
 44 
Obesity is not synonymous with metabolic dysfunction: a role for adipose 45 
morphology? 46 
Overweight and obesity are characterized by increased lipid accumulation in adipocytes; 47 
whereas, weight loss is characterized by reduced lipid accumulation in AT (Eriksson-Hogling et 48 
al., 2015; Goodpaster and Sparks, 2017). Obesity is strongly correlated with metabolic disease – 49 
for every kg increase in body weight, diabetes rates increase linearly (Haffner, 2006). Although 50 
the rising prevalence of overweight and obesity has led to an increased occurrence of metabolic 51 
diseases including diabetes and cardiovascular disease (CVD) (Wilding, 2017), obesity is not 52 
synonymous with metabolic dysfunction. For example, in humans insulin resistance is a major 53 
underlying cause of CVD (Ginsberg, 2000), and is associated with dyslipidemia (Reaven et al., 54 
1967), hypertension (Welborn et al., 1966) and atherosclerosis (Howard et al., 1996). However, 55 
huge variation exists in the degree of insulin resistance across all values of body mass index 56 
(BMI; a surrogate measure of adiposity) (McLaughlin et al., 2004). Indeed, the degree of insulin 57 
resistance can vary six fold at any given BMI (McLaughlin et al., 2004). Therefore, obesity per se 58 
is clearly not the sole driving force for metabolic dysfunction, and understanding which other 59 
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factors are responsible for the unexplained variance in insulin resistance will have important 60 
consequences for public health. Multiple related factors have been proposed to explain 61 
dysfunctional AT, and the variability in insulin resistance, during obesity; including, adipose 62 
inflammation, fibrosis, impaired angiogenesis, hypoxia and body fat distribution (Bluher, 2016; 63 
Crewe et al., 2017; Divoux et al., 2010; Khan et al., 2009; Sun et al., 2011; Trayhurn, 2013; 64 
Weisberg et al., 2003). Here, we present evidence from the literature that adipose morphology is 65 
an additional factor that influences susceptibility to metabolic disease.  66 
 67 
Regional variation in adipose morphology 68 
To assess the role of adipose morphology in metabolic disease, it is first essential to 69 
review how adipose morphology can vary between regionally-distinct ATs. Briefly, ATs are 70 
distributed throughout the human body, but are mainly categorized into subcutaneous ATs (SAT; 71 
AT situated between muscle and skin) and visceral ATs (VAT; AT associated with internal visceral 72 
organs) (Fig. 1A) (Shen et al., 2003). The subcutaneous and visceral sites of adipose 73 
accumulation appear conserved to mouse (Bartelt and Heeren, 2014; Cinti, 2012; Shen et al., 74 
2003), and strikingly, most regional AT sites even appear conserved to zebrafish (Minchin and 75 
Rawls, 2017; Shen et al., 2003). The regional distribution of human AT is strongly associated with 76 
insulin resistance. A recent meta-analysis demonstrated that VAT was the strongest predictor of 77 
insulin resistance (measured by HOMA-IR) (Zhang et al., 2015); however, total fat mass, BMI, 78 
waist circumference, intra-abdominal fat, abdominal fat were also significantly associated with 79 
insulin resistance (Zhang et al., 2015). By contrast, lower-body SAT was not correlated with 80 
insulin resistance and has been shown to protect against metabolic dysfunction (Snijder et al., 81 
2005; Snijder et al., 2004; Zhang et al., 2015). Many previous studies in humans have also linked 82 
accumulation of lipid within abdominal SAT to insulin resistance and metabolic disease, thus 83 
suggesting that upper body (or central adiposity) vs lower body (or peripheral adiposity) body fat 84 
distribution is an important factor in metabolic disease (Karpe and Pinnick, 2015; Porter et al., 85 
2009).  86 
Adipocytes from regionally distinct ATs can be significantly different sizes. For example, 87 
comparison of adipocyte size between three distinct human SATs (gluteal, anterior abdominal 88 
wall and triceps) revealed significant differences (gluteal > abdominal > triceps) (Salans et al., 89 
1973; Salans et al., 1971). Indeed, intra-individual site-to-site variability in adipocyte size was 90 
greater than same site variability between individuals (Salans et al., 1971). In general, across 91 
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studies, SAT adipocytes were significantly larger than VAT adipocytes, irrespective of BMI or 92 
metabolic state (Liu et al., 2009; Tchernof et al., 2006), thus suggesting that SAT undergoes 93 
greater hypertrophy relative to VAT. However, previous studies have suggested that SAT is 94 
inherently more hyperplastic than VAT; although, these observations were based on in vitro data 95 
from mouse and humans showing that SAT-derived cells have greater adipogenic capacity than 96 
VAT-derived cells (Baglioni et al., 2012; Macotela et al., 2012; Tchkonia et al., 2006). More recent 97 
in vivo data using the transgenic AdipoChaser mouse line, have suggested the opposite; following 98 
diet-induced obesity, VAT (epidydimal) undergoes waves of hyperplastic growth, whereas SAT 99 
(inguinal) did not (Wang et al., 2013). Although these data conflict with the in vitro observations 100 
of higher SAT hyperplasia; these findings do conform to the larger adipocyte size, and presumed 101 
greater degree of hypertrophic growth in SAT. Thus, after exposure to a high-fat diet, SAT appears 102 
to preferentially undergo hypertrophic growth which leads to larger adipocytes relative to VAT. 103 
The contrasting growth dynamics of VAT and SAT is of biomedical importance as reduced 104 
expandability of SAT is associated with insulin resistance (Gealekman et al., 2011; Virtue and 105 
Vidal-Puig, 2008). In line with these observations, treatment of obese diabetics with 106 
thiazolidinidiones (TZDs) leads to greater weight gain, preferential lipid deposition in SAT and 107 
improved insulin sensitivity (Fonseca, 2003; Nichols and Gomez-Caminero, 2007). Thus, 108 
understanding the differential growth mechanisms of SAT may provide therapeutic targets for 109 
treating obesity-associated metabolic disease. 110 
 111 
Using a ‘morphology value’ to quantify adipose morphology 112 
To quantify adipose morphology, Arner et al. (2010) described a ‘morphology value’ – the 113 
difference between measured adipocyte volume and expected adipocyte volume (relative to total 114 
adipose mass) (Arner et al., 2010; Spalding et al., 2008) (Fig. 1B). This metric was further utilized 115 
by Veilleux et al. (2011), and facilitated the categorization of individuals according to whether 116 
adipose exhibits a hypertrophic or hyperplastic morphology (Arner et al., 2010; Veilleux et al., 117 
2011). To determine the morphology value, AT biopsies were first taken, then a single-cell 118 
adipocyte suspension was produced by collagenase digestion and buoyancy separation, and the 119 
size of individual adipocytes was then measured using image analysis software. A curvilinear line 120 
was then fitted to the data to best describe the relationship between adiposity and mean adipocyte 121 
size (Spalding et al., 2008). Each individual was then categorized in relation to the fitted line: 122 
individuals exhibiting a positive residual were hypertrophic (mean adipocyte volume larger than 123 
expected); whereas, individuals exhibiting a negative residual were hyperplastic (mean adipocyte 124 
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volume smaller than expected) (Arner et al., 2010; Veilleux et al., 2011) (Fig. 1B). Importantly, 125 
lower morphology values (hyperplastic) were associated with an increased number of small 126 
adipocytes; whereas, high morphology values (hypertrophic) were associated with fewer, larger 127 
adipocytes (Arner et al., 2010; Veilleux et al., 2011). Within a population, adipose morphology 128 
appears highly variable. Arner et al. (2010) found that hyperplastic and hypertrophic morphologies 129 
were present at equal frequencies in both males vs females, and obese vs non-obese (Arner et 130 
al., 2010). Strikingly, at comparable BMI, women typically present with ~10% higher body fat, 131 
characterized with greater SAT in the abdomen and gluteofemoral regions (Camhi et al., 2011; 132 
Jackson et al., 2002; Karastergiou et al., 2012; Womersley, 1977). Body fat distribution is linked 133 
to health in both males and females; however, the protective peripheral distribution is mainly seen 134 
in females (Krotkiewski et al., 1983). Large inter-individual variation in adipocyte number and size 135 
within equivalent ATs was also observed, which was independent of adipose mass (Arner et al., 136 
2011; Salans et al., 1973; Salans et al., 1971). Furthermore, estimates for adipocyte number 137 
varied by as much as 85% between individuals (Salans et al., 1973), suggesting a high-level of 138 
inter-individual variability in adipose morphology. Intriguingly, adipocyte number and size were 139 
highly similar in monozygotic twins concordant for BMI, suggesting a strong genetic basis 140 
(Heinonen et al., 2014). Therefore, understanding how genetics drives variation in adipose 141 
morphology with subsequent consequences for disease risk is a central research question.  142 
 143 
Hypertrophic morphology is associated with insulin resistance and increased risk 144 
for cardiovascular disease  145 
The association between SAT morphology and metabolic disease has been extensively 146 
characterized. In a cohort of 764 subjects exhibiting a wide adiposity range (BMI 18-60 kg/m2), 147 
Arner et al. (2010) found that hypertrophic morphology was positively correlated with insulin 148 
resistance (measured by HOMA-IR) and fasting plasma Insulin in humans (Arner et al., 2010). 149 
Furthermore, in women, hypertrophic morphology was associated with a metabolic syndrome-like 150 
state, characterized by increased insulin resistance, and increases in circulating plasma Insulin, 151 
total cholesterol and TAG (Arner et al., 2010). Additionally, abdominal SAT adipocyte size by itself 152 
was positively associated with insulin resistance independent of BMI in non-diabetic humans 153 
(Lundgren et al., 2007). Further, SAT adipocyte size was positively associated with plasma 154 
Insulin, glucose, Insulin-induced glucose disposal and insulin sensitivity in humans (Hoffstedt et 155 
al., 2010). Finally, in humans, the average volume of adipocytes within abdominal SAT was 156 
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correlated with insulin resistance (Yang et al., 2012). By contrast, hyperplastic morphology was 157 
associated with significantly better blood glucose, Insulin and lipid profiles when compared to 158 
subjects with hypertrophic morphology (Hoffstedt et al., 2010). Taken together, these data 159 
demonstrate that hypertrophic SAT morphology is associated with metabolic dysfunction, and 160 
metabolic risk factors for diabetes and CVD. VAT morphology has also been implicated in 161 
metabolic disease. In a sample of 207 lean to severely obese females, subjects characterized by 162 
hypertrophic omental VAT had higher plasma TAG, higher very low density lipoprotein (vLDL)-163 
TAG and higher vLDL-cholesterol when compared to subjects with hyperplastic VAT (Veilleux et 164 
al., 2011). It was also estimated that a 10% enlargement of VAT adipocytes increased the risk of 165 
hypertriacylglyceridemia 4-fold (Veilleux et al., 2011); whilst, a 10% increase in the number of 166 
VAT adipocytes increased the risk of hypertriacylglyceridemia by 1.55-fold (Veilleux et al., 2011). 167 
In morbidly obese females, and independent of age, BMI, body fat mass or body fat distribution, 168 
VAT adipocyte size was positively associated with plasma apolipoprotein B, total cholesterol, 169 
vLDL-cholesterol and triacylglycerides (Hoffstedt et al., 2010). Furthermore, large VAT adipocytes 170 
(>75 µm diameter) were associated with insulin resistance in canines (Kabir et al., 2011). These 171 
data demonstrate that hypertrophic VAT morphology is also associated with a metabolic-172 
syndrome-like state. 173 
 174 
Bi- and tri-modal adipocyte size distributions: a more complex relationship 175 
between adipose morphology and Insulin resistance? 176 
Many studies have concluded that adipocytes comprise a complex population of cells that 177 
exhibit a bi- or tri-modal size distribution. In general, these studies have used osmium tetroxide 178 
fixation of adipocytes, followed by size analysis of adipocytes using a Coulter counter (Cushman 179 
and Salans, 1978; Etherton et al., 1977; Hirsch and Gallian, 1968). The advantages of this method 180 
include the ability to analyze large numbers of adipocytes (~6000 cells from each subject), and 181 
the automated and unbiased measurement of adipocyte size (Jo et al., 2012). To exclude the 182 
possibility that the small adipocytes (within a bimodal population) were not artefactual ‘debris’, it 183 
was confirmed by microscopy that these cells were comprised of intact, spherical small adipocytes 184 
(McLaughlin et al., 2007). In addition to osmium tetroxide fixation, measurement by microscopy 185 
has also indicated that adipocytes may form a bimodal size distribution (Fang et al., 2015). 186 
Comparison of the size distributions obtained from these methods revealed a peak of small 187 
adipocytes of ~25 µm diameter, and a peak of larger adipocytes of ~50 µm diameter (Fig. 2) (Jo 188 
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et al., 2012). Intriguingly, trimodal adipocyte size distributions in humans have also been observed 189 
with peaks at ~25, ~50 and ~100 µm diameters  (Yang et al., 2012). Recently, 3D reconstruction 190 
of zebrafish VAT revealed a bimodal size distribution of adipocyte-localized LDs (Minchin et al., 191 
2015). However, it is likely that the smaller population of LDs (~1 µm in diameter) correspond to 192 
additional LD ‘locules’ within multilocular adipocytes – a phenomenon also observed in human 193 
and mouse white adipocytes (Chau et al., 2014; Cushman, 1970). Together, these studies 194 
suggest that parametric statistics, such as mean adipocyte size and number, may not accurately 195 
represent the true population mean, and should be used with caution when assessing adipose 196 
morphology. 197 
Multiple studies have confirmed that the size of larger adipocytes in a bimodal population 198 
is positively associated with metabolic dysfunction. First, McLaughlin et al. (2014) found that 199 
compared to BMI-matched insulin sensitive subjects, insulin resistant subjects had larger ‘large’ 200 
adipocytes within abdominal SAT. Second, in 35 subjects (with BMI ranging from 18-34 kg/m2) 201 
the size of larger adipocytes within abdominal SAT was able to accurately predict insulin 202 
resistance (Yang et al., 2012). Third, in insulin sensitive obese individuals, an increase in size of 203 
the larger adipocyte fraction within abdominal SAT after feeding a hypercaloric diet, predicted a 204 
decline in Insulin-mediated glucose uptake (McLaughlin et al., 2016). In addition to insulin 205 
resistance, the size of the large adipocytes was also correlated with an increased VAT/VAT+SAT 206 
ratio (Kursawe et al., 2010), an increased proportion of small adipocytes in both VAT and SAT 207 
(Liu et al., 2009), and the normalization of insulin sensitivity in insulin resistant subjects after 208 
treatment with rosiglitazone (Eliasson et al., 2014). A summary of these findings is provided in 209 
Table 1. Taken together these studies show that hypertrophied adipocytes within the larger 210 
fraction of adipocytes in a bimodal population is also associated with insulin resistance.   211 
The proportion and size of small adipocytes within a bimodal size distribution is also 212 
related to metabolic wellbeing. In moderately overweight/obese individuals, McLaughlin et al. 213 
(2007 & 2014) found an increased proportion of small adipocytes in abdominal SAT to be 214 
statistically associated with Insulin resistance, Further, an increased proportion of small 215 
adipocytes was found in both abdominal SAT and omental VAT of diabetics (Fang et al., 2015). 216 
Intriguingly, an increased proportion of small adipocytes in abdominal SAT also occurred in 217 
subjects with high VAT/VAT+SAT ratio (Kursawe et al., 2010), after insulin sensitive subjects were 218 
overfed (McLaughlin et al., 2016), or after diabetics were treated with rosiglitazone (Eliasson et 219 
al., 2014). In diabetics, the size of small adipocytes was also found to be inversely correlated with 220 
insulin sensitivity (Fang et al., 2015).  Finally, an expanded nadir (the low point in frequency 221 
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between the small and large adipocyte populations) was found in insulin resistant subjects 222 
(McLaughlin et al., 2007). A summary of these findings is provided in Table 1. Together, these 223 
data show that insulin resistance is not only accompanied by hypertrophy of large adipocytes, but 224 
in studies that detect a bimodal adipocyte size distribution, insulin resistance is also associated 225 
with an increased proportion of small adipocytes. Related to the increased presence of small 226 
adipocytes, the expression of genes related to adipogenesis was also lower in insulin resistant 227 
individuals (McLaughlin et al., 2007). These findings are consistent with independent reports of 228 
reduced adipogenesis in insulin resistant patients (Goedecke et al., 2011; Yang et al., 2004). 229 
Further, these expression changes were also associated with modest increases in inflammatory 230 
activity in insulin resistant AT (McLaughlin et al., 2008). As the presence of small adipocytes in 231 
both VAT and SAT appears to be correlated with increased hypertrophy of larger adipocytes in 232 
abdominal SAT (Liu et al., 2009), these findings could be interpreted to suggest that SAT is the 233 
primary site for lipid accumulation; however, once a maximal SAT adipocyte size is reached, 234 
hyperplastic growth is initiated in both VAT and SAT. In support, adipocytes have been shown to 235 
expand to only a finite degree in both humans and rats (Faust et al., 1978; Kashiwagi et al., 1985). 236 
A summary of these findings is provided in Table 1. Therefore, these data suggest that insulin 237 
resistance is accompanied by an inability of small adipocytes to undergo hypertrophic expansion, 238 
suggestive of defective adipogenesis, resulting in a higher proportion of small adipocytes amongst 239 
a more general population of hypertrophied adipocytes. 240 
 241 
Transcriptomic differences in distinct adipose morphologies 242 
To study adipose hypertrophy and hyperplasia, and to identify potential molecular 243 
pathways that influence morphology, it is useful to analyze the transcriptional state underlying 244 
distinct morphologies. Strikingly, adipocytes of different sizes have distinct gene expression 245 
profiles. Jernas et al. (2006) fractionated human adipocytes into small (mean diameter 57.6 ± 246 
3.54 µm) or large (mean diameter 100.1 ± 3.94 µm) groups. Subsequent microarray analysis of 247 
gene expression on the 2 groups of adipocytes revealed 14 genes with 4-fold higher expression 248 
in large adipocytes (Table 2) (Jernas et al., 2006). Strikingly, some transcripts exhibited 19-fold 249 
and 22-fold higher expression in large adipocytes, suggesting relatively large-scale differences 250 
between adipocytes based on size (Jernas et al., 2006). In an additional study, Heinonen et al. 251 
(2014) analyzed whether adipocyte size or number correlated with changes in the AT 252 
transcriptome. RNA was extracted from whole-adipose biopsies (including both adipocyte and 253 
stromal-vascular fractions), and gene expression changes positively correlating with adipocyte 254 
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size included, genes implicated in cell cytoskeleton and membrane modifications (MSN, 255 
NHEDC2, KIF3B, PALLD), oxidative stress and apoptosis (MSN), cell mediated immunity (MIF) 256 
and cancer (NMES) (Tables 2 & 3) (Heinonen et al., 2014). Genes inversely correlated with 257 
adipocyte size include FDFT1 (mevalonate pathway, cholesterol biosynthesis), ADH1B 258 
(metabolism of a wide range of substrates, including hydroxysteroids and lipid peroxidation 259 
products), EIF1B (unknown function) (Tables 2 & 3) (Heinonen et al., 2014). Significant Gene 260 
Ontology (GO) terms, used to describe shared relationships between sets of genes, revealed that 261 
leukocyte migration and immune system processes were significantly enriched terms in genes 262 
upregulated in large adipocytes (Table 4). Adiponectin mRNA was also found to be negatively 263 
associated with size in isolated adipocytes (Bambace et al., 2011); whereas, Leptin mRNA was 264 
positively associated with adipocyte volume in isolated adipocytes (Guo et al., 2004). However, 265 
Leptin mRNA per unit of fat mass decreased at more extreme levels of obesity (Guo et al., 2004). 266 
Skurk et al. (2007) analyzed the relationship between adipocyte size and secreted factors and 267 
found that Leptin, IL6, IL8, MCP1 and G-CSF were significantly increased in large adipocytes, 268 
supportive of altered immune signaling following hypertrophy (Skurk et al., 2007). Recently, Gao 269 
et al (2014) utilized adipose biopsies from a cohort of 56 healthy males and females, subdivided 270 
into obese or non-obese individuals with hyperplastic or hypertrophic morphologies (ie, obese 271 
hyperplastic, obese hypertrophic, non-obese hyperplastic and non-obese hypertrophic) (Gao et 272 
al., 2014). This analysis identified 619 genes differentially altered by morphology in non-obese 273 
subjects (Gao et al., 2014). Genes increased in non-obese hypertrophy were associated with pro-274 
inflammatory pathways; whereas, genes increased n non-obese hyperplasic individuals where 275 
involved in carbohydrate and lipid metabolism (Gao et al., 2014). The transcriptome of adipocytes 276 
in bimodal size distributions have also been analyzed. Liu et al. (2010) characterized small 277 
adipocytes from epidydimal AT (VAT) of Zucker Obese (ZO) and Lean (ZL) rats and found that 278 
small adipocytes had a 3-fold decrease in Adiponectin and Pparg in ZO versus ZL rats (Liu et al., 279 
2010), along with a 2.5-fold increase in IL-6 (Liu et al., 2010). These data suggest that both 280 
hypertrophied adipocytes, and the small adipocytes from a bimodal population have pro-281 
inflammatory characteristics. Altogether, these data support the conclusion that small and large 282 
adipocytes have distinct transcriptional profiles, and that large adipocytes are characterized by 283 
altered immune/inflammatory activity. 284 
 285 
Cellular mechanisms hypothesized to regulate adipose morphology 286 
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Understanding the cell and molecular mechanisms that underpin adipose morphology is 287 
likely to provide new therapeutic targets for combating obesity-associated disease. For simplicity, 288 
we have separated the factors that are likely to influence adipose morphology into two categories: 289 
(i) factors that regulate adipocyte number and (ii) factors that regulate adipocyte size. As the 290 
regulation of adipocyte number (adipogenesis) is a well-studied subject with many in-depth 291 
reviews (Berry et al., 2016; Berry et al., 2014; Hepler et al., 2017), we will focus on mechanisms 292 
hypothesized to regulate adipocyte size. Surprisingly, relatively few studies have identified cellular 293 
mechanisms that regulate adipocyte size. Therefore, we first review highly conserved 294 
mechanisms for regulating cell size across multiple cell types, and investigate whether these 295 
conserved mechanisms may also regulate adipocyte size. We then focus on two interesting, 296 
adipocyte-specific pathways that regulate adipocyte size: how the phospholipid monolayer on the 297 
surface of LDs controls their expansion, and the emerging field of osmolarity sensors in regulating 298 
adipocyte hypertrophy. 299 
 300 
A role for mTORC1 in regulating adipocyte size: a highly conserved signaling 301 
pathway that control cell size across multiple diverse cell types.  302 
 Highly conserved homeostatic mechanisms regulate cell size in eukaryotes (Lloyd, 2013). 303 
As adipocyte size is also highly regulated we reasoned that understanding the core pathways that 304 
maintain cell size, across multiple diverse cell types, has the potential to shed light on 305 
mechanisms controlling adipocyte hypertrophy. Central to the control of cell size across the 306 
animal kingdom is the Insulin Growth Factor (IGF), Phosphoinositide 3-kinase (PI3K), Protein 307 
kinase B (AKT), and Mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway. 308 
IGF/PI3K/AKT/mTORC1 coordinates nutrition with cell growth, and acts as a node to integrate 309 
external signals, including Insulin signalling, with biogenic pathways (Edgar, 2006). mTORC1 310 
responds to multiple inputs, including; amino acids, energy, stress, oxygen and growth factors, 311 
and regulates downstream anabolic processes that promote cell growth, including; protein and 312 
lipid synthesis (through SREBP1/2), mitochondria biogenesis, and ATP production (Cunningham 313 
et al., 2007; Duvel et al., 2010; Ma and Blenis, 2009; Porstmann et al., 2008). In addition, 314 
mTORC1 also promotes cell growth by negatively regulating autophagy (Hosokawa et al., 2009). 315 
Strikingly, artificial activation of the mTORC1 pathway promotes dramatic increases in cell size 316 
(Laplante and Sabatini, 2012).  Altogether, these data suggest that activation of mTORC1 317 
signaling may induce and augment adipocyte hypertrophy. In accordance, Raptor KO mice 318 
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(Raptor is an mTOR binding protein essential for formation, and activity of the mTORC1 complex) 319 
have smaller adipocytes (and a reduced number), suggesting that mTORC1 may promote 320 
adipocyte hypertrophy (Polak et al., 2008). Indeed, Raptor KO mice, with specific loss of Raptor 321 
and mTORC1 in adipocytes, develop lipodystrophy with age, suggesting that mTORC1 is 322 
essential for maintaining a hypertrophic state in mature adipocytes (Lee et al., 2016). 323 
Furthermore, adipocyte-specific Raptor KO led to the induction of a bimodal ‘polarized’ adipocyte 324 
size distribution, characterized by the addition of a small population of adipocytes, further 325 
suggesting that mTORC1 is essential for maintaining adipose morphology (Lee et al., 2016). Such 326 
a polarized adipocyte size distribution is reminiscent of fat-specific insulin receptor knockout 327 
(FIRKO) mice (Bluher et al., 2002), suggesting that Insulin signalling maybe critically important 328 
for maintaining adipose morphology. Elevated mTORC1 signaling, produced after deletion of 329 
tuberous sclerosis complex 2 (Tsc2) – a complex made up of Tsc1 & 2 proteins that inhibits 330 
mTORC1 signaling, led to increased adipogenesis in mouse fibroblasts and 3T3-L1 adipocytes 331 
(Zhang et al., 2009). However, in vivo constitutive activation of mTORC1 in adipocytes by 332 
tuberous sclerosis complex 1 (Tsc1) deletion, did not induce adipocyte hypertrophy but instead 333 
led to reduced VAT mass, VAT adipocyte number and diameter without affecting SAT, pointing 334 
to the complex nature of mTORC1 signaling in adipocytes (Magdalon et al., 2016). Taken 335 
together, mTORC1 depletion leads to adipose atrophy; however, conclusive evidence for a role 336 
for mTORC1 in adipocyte hypertrophy has not been fully elucidated. 337 
 338 
The availability of lipid as a rate-limiting step for adipocyte hypertrophy  339 
The single defining feature of white adipocytes is the presence of large cytoplasmic LDs 340 
that can reach ~200 µm in diameter (Walther and Farese, 2009). This feature is unique to white 341 
adipocytes and, therefore, we reasoned that understanding how LD growth is regulated may also 342 
allow us to elucidate cellular mechanisms underlying adipocyte hypertrophy. LD size reflects two 343 
processes: (i) lipid incorporation into LDs and (ii) lipid mobilization from LDs. However, each of 344 
these processes is highly complex and can be regulated at multiple levels. For example, at a 345 
minimum, lipid incorporation into LDs depends on (i) circulating levels of lipid (i.e. availability of 346 
lipid to adipocytes), (ii) lipid uptake into adipocytes, (iii) re-esterification of non-esterified fatty 347 
acids (NEFAs) into TAG, and (iv) de-novo lipogenesis in adipocytes, (v) incorporation of TAG into 348 
LDs (Fig. 3A). Lipid synthesis, transport and metabolism in adipocytes is a large subject area 349 
beyond the scope of this review; however, we recommend the following reference for further 350 
reading on the subject (Large et al., 2004). Briefly, however, and as described above, hypertrophic 351 
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VAT was associated with higher plasma TAG, vLDL TAG and cholesterol, total plasma 352 
cholesterol, higher total-to-HDL cholesterol and increased plasma apolipoprotein B when 353 
compared to hyperplastic VAT (Hoffstedt et al., 2010; Veilleux et al., 2011). Together, these data 354 
suggest that increased circulating lipid may promote hypertrophic growth of adipocytes. 355 
Accordingly, treatment of 3T3-L1 adipocytes with saturated or monounsaturated NEFAs resulted 356 
in adipocyte hypertrophy (Kim et al., 2015). Regarding uptake of lipid into adipocytes, the first 357 
step is often hydrolysis of TAG from circulating lipoproteins by Lipoprotein lipase (LPL). In adipose 358 
tissue, LPL is expressed on vascular endothelial cells and adipocytes (Gonzales and Orlando, 359 
2007; Merkel et al., 2002), and hydrolyses TAG (from lipoproteins) to form glycerol and NEFAs 360 
for uptake into adipocytes (Geldenhuys et al., 2017). In SAT, higher levels of LPL activity were 361 
associated with adipocyte hypertrophy (Serra et al., 2015). Further, LPL deficiency in mice results 362 
in lipodystrophy and elevated plasma lipid levels (Weinstock et al., 1995). Following their 363 
production by LPL, NEFAs are taken up by adipocytes using specialized fatty acid transporters, 364 
including Fatty acid transport proteins (FATPs), the scavenger receptor CD36, and the 365 
mitochondrial aspartate amino transferase (FABPpm). In particular, isolated adipocytes from 366 
CD36 KO mice have impaired NEFA uptake (Coburn et al., 2000). Further, CD36-deficient mice 367 
do not develop diet-induced obesity, suggesting that adipocyte hypertrophy is impaired (Hajri et 368 
al., 2007; Koonen et al., 2010; Vroegrijk et al., 2013). We speculate that increased circulating lipid 369 
causes adipocyte hypertrophy and adipose growth; however, there is currently limited evidence 370 
that circulating lipid levels induce a hypertrophic morphology as defined by Arner et al. (2010). 371 
Altogether, these data suggest that lipid availability, in the form of plasma lipid levels, LPL activity 372 
and lipid uptake into cells, is key to promoting adipocyte hypertrophy. 373 
 374 
Specialized pathways for regulating lipid droplet size in adipocytes  375 
Large cells, such as neurons and ova, often have specialized mechanisms that allow them 376 
to grow to extreme sizes (Lloyd, 2013). Therefore, it is likely that adipocytes have adipocyte-377 
specific pathways that govern their hypertrophic capacity. Multiple intriguing mechanisms regulate 378 
LD growth. First, a genome-wide screen in yeast identified 10 mutants that produced “supersized” 379 
LDs, capable of forming LDs >50 times larger than wild-type LDs (Fei et al., 2011). The genes 380 
identified include yeast homologs of Seipin (Fei et al., 2008; Fei et al., 2011), regulators of 381 
phospholipid metabolism, and multiple subunits of casein kinase 2 (Fei et al., 2011). Phosholipid 382 
metabolism was a shared feature of the genes identified from the screen, and the surface layer 383 
of LDs are coated with a phospholipid monolayer (Walther and Farese, 2009). Phosphatidic acid 384 
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(PA), a cone-shaped lipid common in phospholipids which alters the curvature of membranes, 385 
and promotes membrane fusion events, was a key factor in formation of supersized LDs (Fei et 386 
al., 2011; Marchesan et al., 2003). Further, supersized LDs could be formed by PA-stimulated 387 
fusion of LDs (Fei et al., 2011), suggesting that the phospholipid monolayer of LDs is important 388 
for LD growth and may mediate LD fusion to facilitate LD hypertrophy.   389 
 390 
Regulation of adipocyte size by osmolarity-sensing ion channels 391 
 Cells respond to changes in size by generating osmotic gradients using plasma membrane 392 
ion channels and transporters to manipulate the osmolarity of the surrounding environment. 393 
Utilizing of these on channels can create a hypotonic environment leading to cell swelling (RVI; 394 
regulatory volume increase), or a hypertonic environment leading to cell shrinkage (RVD; 395 
regulatory volume decrease) (Fig. 3B) (Hoffmann et al., 2009; Jentsch, 2016). As cell size 396 
regulation is central to the dynamic growth and regression of adipocytes, the role of such 397 
osmosensers and regulators is under intense investigation. Transient receptor potential cation 398 
channel subfamily V member 4 (TRPV4) is a Ca2+-permeable, nonselective cation channel 399 
involved in the regulation of osmotic pressure (Harteneck and Reiter, 2007), and is activated by 400 
cellular swelling and stretch (Liedtke et al., 2000; Mochizuki et al., 2009; Strotmann et al., 2000; 401 
Thodeti et al., 2009). Adipocytes from TRPV4 KO mice do not undergo hypertrophy and 402 
underwent increased oxidative metabolism (Ye et al., 2012) (Fig. 3C). Additionally, the TRPV4 403 
KO mice were protected from diet-induced obesity, adipose inflammation and Insulin resistance 404 
(Ye et al., 2012). Thus, TRPV4 promotes adipocyte hypertrophy, and may contribute to the Insulin 405 
resistance inherent to hypertrophied adipocytes. Recently the voltage-regulated anion channel 406 
(VRAC), SWELL1 (LRCC8A), was shown to regulate adipocyte size, Insulin signaling and glucose 407 
homeostasis (Zhang et al., 2017). VRACs export chloride ions (Cl-) and other small organic 408 
osmolytes, and thus generate a hypertonic environment that induces cell shrinkage (RVD) 409 
(Jentsch, 2016; Qiu et al., 2014). Zhang et al. (2017) utilized patch-clamp recordings of ionic 410 
currents in freshly isolated adipocytes to identify that hypertrophic adipocytes exhibit an increased 411 
‘swell-activated’ Cl- current relative to smaller adipocytes (Zhang et al., 2017). Furthermore, the 412 
increased current observed in hypertrophied adipocytes was dependent on SWELL1. Although 413 
activation of VRACs has generally been shown to induce RVD and decrease cell volume (Jentsch, 414 
2016), the authors propose that SWELL1-mediated expansion acts as a feed-forward amplifier 415 
for further adipocyte hypertrophy (Fig. 3C). Further, SWELL1 knockout (KO) adipocytes were 416 
Insulin resistant with reduced GLUT4 translocation to the adipocyte plasma membrane after 417 
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stimulation with Insulin (Zhang et al., 2017). This effect was found to be mediated by PI3K-AKT 418 
signaling, and SWELL1 KO adipocytes had reduced phosphorylation of AKT (Zhang et al., 2017). 419 
Thus, taken together, these data suggest that osmosensing is active in adipocytes during 420 
hypertrophy, and may modulate adipocyte hypertrophy and Insulin sensitivity. In addition to ion 421 
channel osmosensers, the adipocyte plasma membrane contains abundant caveolae, small flask-422 
shaped invaginations of the plasma membrane enriched in cholesterol and sphingolipids, which 423 
disassemble in response to osmotic and mechanical stress (Sinha et al., 2011). Caveolae are 424 
present at a high density in cells that experience mechanical stress, and cover ~30% of the 425 
adipocyte surface (Le Lay et al., 2015). Caveolae formation is driven by the assembly of 3 distinct 426 
Caveolin proteins (Cav1-3), and deletion of individual Cav genes leads to loss of caveolae (Le 427 
Lay and Kurzchalia, 2005). Caveolae mediate the response of several cell types to mechanical 428 
stress (Boyd et al., 2003; Sedding et al., 2005), and intriguingly, loss of caveolae induces 429 
lipodystrophy in mice and humans (Kim et al., 2008; Razani et al., 2002). Further, overexpression 430 
of Cav1 in adipocytes induced an increase in caveolae density, but also stimulated the 431 
accumulation of larger LDs (Fig. 3C) (Briand et al., 2014). No role for caveolae as an 432 
osmosensor/regulator during adipocyte hypertrophy is known; however, it is clear that caveolae 433 
are essential for lipid storage fluctuations in adipocytes. 434 
 435 
Conclusion 436 
At a population level, adipose morphology is highly varied, genetically determined and associated 437 
with cardiometabolic disease susceptibility. However, the precise genetic determinants of adipose 438 
morphology are largely unknown. In this Review, we find strong evidence in the literature that a 439 
hypertrophic morphology, adipose characterized by few but large adipocytes, is associated with 440 
a range of metabolic perturbances including plasma glucose, lipid and Insulin levels, insulin 441 
resistance and susceptibility to disease. We further review whether distinct morphologies have 442 
unique transcriptomic signatures, and identify that hypertrophic morphology is characterized by a 443 
pro-inflammatory expression profile across multiple studies and methodologies. Finally, we 444 
explore some intriguing cellular mechanisms that are predicted to regulate adipocyte cell size and 445 
morphology; including (i) how the phospholipid monolayer covering lipid droplets regulates their 446 
growth, and (ii) how osmolarity sensing in adipocytes can stimulate hypertrophy.   447 
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Table 1. Human adipose morphology and metabolic parameter associations – bimodal 769 
adipocyte size distribution. 770 
Morphology 
trait 























































































































































*Cohort was 28 obese individuals (mean age = ~50 years) stratified according to Insulin sensitivity 771 
(Insulin resistant BMI = 30.6 kg/m2; Insulin sensitive BMI = 29.4 kg/m2). No statistical differences 772 
between Insulin resistant and sensitive groups were found for age, gender, reported levels of 773 
exercise, blood pressure, fasting glucose, total cholesterol, LDL-cholesterol. HDL-cholesterol 774 
were lower in Insulin resistant group. 775 
**Cohort was 38 adolescents (~ 15 years old) with similar degrees of obesity (mean BMI = ~37 776 
kg/m2) were divided into 2 groups: low VAT/VAT+SAT ratio (<0.11) and high VAT/VAT+SAT ratio 777 
(>0.11). None of the participants were on any medication or had any known disease. 778 
***Cohort was 11 obese (mean BMI = 45.3 kg/m2) Insulin resistant, but non-diabetic women. 779 
Patients were excluded if they had coronary heart disease, hepatic or renal disease, cancer, or 780 
use medications for weight loss. 781 
****Cohort was 35 subjects with a range of BMI (range = 18-34 kg/m2; mean = 25.7 kg/m2) and 782 
age (range = 28-49 years; mean = 41 years). The subjects were non-diabetic, but had a known 783 
family history of diabetes, with at least 2 first-degree relatives with type 2 diabetes. 784 
^Cohort was 12 patients with type 2 diabetes (11 male, 1 female). Patients had a mean BMI of ~ 785 
28 kg/m2. Patients were on diet or oral hypoglycemic treatments including sulfonylurea, 786 
repaglinide and metformin). Rosiglitazone (8 mg QD) was added to the treatment regimen. 787 
Subjects were excluded if they exhibited clinically significant disease. Adipose biopsies were 788 
taken before and after rosiglitazone treatment. 789 
^^Cohort was 30 subjects with morbid obesity. Adipose biopsies were taken from subcutaneous, 790 
omental and mesenteric locations. 791 
^^^Cohort consisted of healthy overweight adults, aged 30-60 years. BMI = 25-35 kg/m2.Subjects 792 
had a stable body weight during the prior 3 months, and fasting plasma glucose <126 mg/dL. 793 
Subjects were given a hypercaloric diet to induce 3.2 kg weight gain over 4 weeks, followed by 1 794 
week of weight stabilization. 795 
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Table 2. Genes positively correlated with adipocyte size. 797 
Gene symbol Gene name Study PMID 
SELE Selectin E 16754744 
SPARCL1 SPARC-like 1 16754744 
TM4SF1 Transmembrane 4 L six family member 1 16754744 
DCN Decorin 16754744 
IL8 Interleukin 8 16754744 
PALLD Palladin 16754744, 24549139 
SAA2 Serum amyloid A2 16754744 
CLEC3B C-type lectin domain family 3, member B 16754744 
C1QR1 Complement component 1, q subcomponent, 
receptor 1 
16754744 
COL1A1 Collagen, type I, alpha 1 16754744 
CXCL2 Chemokine (C-XC motif) ligand 1 16754744 
COL1A2 Collagen, type I, alpha 2 16754744 
FLJ14054  16754744 
AQP1 Aquaporin 1 16754744 
MSN Moesin 24549139 
NHEDC2 Na+/H+ exchanger domain containing 2 24549139 
RP11-877E17.2 undefined 24549139 
KIF3B Kinesin family member 3B 24549139 
NME5 Non-metastatic cells 5, protein expressed in 
(nucleoside-diphosphate kinase) 
24549139 
IFT20 Intraflagellar transport  
20 homolog  
(Chlamydomonas) 
24549139 
MIF Macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 
24549139 
SLC24A3 Solute carrier family 24  
(sodium/potassium/calci 
um exchanger),member 3 
24549139 
C15orf59 Chromosome 15 open reading frame 59 24549139 
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CD248 CD248 molecule,  
endosialin 
24549139 
SLC46A3 Solute carrier family 46,  
member 3 
24549139 
XPO6 Exportin 6 24549139 
FAT1 FAT tumor suppressor  
homolog 1 (Drosophila) 
24549139 
GNG2 Guanine nucleotide  
binding protein (G protein), gamma 2 
24549139 
LPCAT1 Lysophosphatidylcholine  
acyltransferase 1 
24549139 
TCTA T-cell leukemia translocation altered gene   24549139 
CLTB Clathrin, light chain B 24549139 
SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 24549139 
CYBASC3 Cytochrome b, ascorbate dependent 3 24549139 
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Table 3. Genes inversely correlated with adipocyte size. 799 
Gene symbol Gene name Study PMID 
NPEPPS Aminopeptidase puromycin sensitive     24549139 
GLYCTK Glycerate kinase 24549139 
PKP2 Plakophilin 2 24549139 
AZGP1 Alpha-2-glycoprotein 1, zinc-binding 24549139 
CIDEA Cell death-inducing DFFA-like effector a 24549139 
FAM184A Family with sequence similarity 184, member A 24549139 
NUP98 Nucleoporin 98kDa 24549139 
WHSC2 Wolf-Hirschhorn syndrome candidate 2 24549139 
FAM161A Family with sequence similarity 161, member A 24549139 
SLC27A2 Solute carrier family 27 (fatty acid transporter), 
member 2 
24549139 
ZFAND1 Zinc finger, AN1-type domain 1 24549139 
MACROD1 MACRO domain containing 1 24549139 
PPARA Peroxisome proliferator-activated receptor alpha 24549139 
GPD1L Glycerol-3-phosphate dehydrogenase 1-like 24549139 
BBC3 BCL2 binding component  
3 
24549139 
CYP3A7 Cytochrome P450, family 3, subfamily A, 
polypeptide 7 
24549139 
TOE1 Target of EGR1, member 1 (nuclear) 24549139 
EIF1B Eukaryotic translation initiation factor 1B 24549139 
ADH1B Alcohol dehydrogenase 1B (class I), beta 
polypeptide 
24549139 
FDFT1 Farnesyl-diphosphate farnesyltransferase 1 24549139 
 800 
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Table 4. Significant GO terms shared among genes positively correlated with adipocyte 802 
size (both studies). 803 




GO:0048522 positive regulation of cellular 
process 






GO:0006928 movement of cell or subcellular 
component 




GO:0050900 leukocyte migration 0.005651237 CXCL2, IL8, MIF, 
COL1A1 
GO:0002376 immune system process 0.007058561 CD248, CXCL2, 
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Figure legends 806 
Figure 1. Schematic illustrating regional adipose morphology. A. This review largely 807 
concentrates on 3 human ATs; visceral (VAT; blue), abdominal SAT (yellow) and gluteofemoral 808 
SAT (red). B. Adipose morphology can be categorized by finding a line-of-best-fit to describe the 809 
relationship between fat mass (mg) and mean adipocyte volume (pl). Such a fitted line produces 810 
a curvilinear relationship (dotted line). AT from individuals (black circles) is assessed relative to 811 
the fitted line (dotted line). A positive residual (adipocyte volume greater than expected) indicated 812 
hypertrophic morphology, whereas an adipocyte volume smaller than expected denotes 813 
hyperplastic morphology. C. Adipose morphology can be hyperplastic characterized by many, 814 
small adipocytes. Or, hyperptrophic, characterized by few, large adipocytes. Each morphology is 815 
associated with distinct metabolic parameters (Arner et al. 2010). 816 
 817 
Figure 2. Schematic illustrating common adipocyte size distributions. A,B. A unimodal 818 
adipocyte size distribution is often found and in obesity, or after exposure to a high-fat diet 819 
(magenta) the population mean (µ) shifts to a larger size. C,D.  A bimodal adipocyte size 820 
distribution can be evaluated by; (i) the value for the nadir (n), (ii) centre of peak (Cp) of large 821 
adipocytes. In obesity, the nadir and centre of peak for the large adipocytes is increased.  822 
 823 
Figure 3. Schematic illustrating putative mechanisms that regulate adipocyte hypertrophy. 824 
A. Lipid availability is critical to adipocyte hypertrophy, and can be split into multiple steps. 1) 825 
circulating lipid in lipoproteins (for example, very Low Density Lipoprotein (vLDL)) can contain 826 
TAG, and the plasma levels of lipoproteins is associated with adipocyte hypertrophy. 2) Hydrolysis 827 
of TAG from lipoproteins is performed by LPL (and GPIHBP1) on the surface of adipocytes of 828 
vascular endothelial cells and produces non-esterified fatty acids (NEFAs) and glycerol. Levels 829 
and activity of LPL is associated with adiposity levels and plasma lipid levels. 3) NEFAs are taken 830 
up into adipocytes by fatty acid transporters such as CD36 (and also FATPs). CD36 levels are 831 
associated with adipocyte hypertrophy. 4) Intracellular NEFAs are re-esterified into TAG in 832 
conjunction with the endoplasmic reticulum (6). De-novo lipogenesis within adipocytes also 833 
contributes to the TAG pool (5). 6) Lipid droplets can grow large or small based on transfer of 834 
lipogenic enzymes (eg, DGAT, diglyceride acyltransferase) from the endoplasmic reticulum 835 
membrane to the LD membrane (Wilfling et al., 2013). 7) TAG within LDs is mobilized (lipolysis) 836 
by lipases including HSL (hormone sensitive lipase). 8) NEFAs are released from adipocytes by 837 
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active transport mechanisms including by ABC transporters (Tarling et al., 2013). B. Osmolarity 838 
is defined as either hypertonic which induces regulated volume decreases (RVD), or hypotonic 839 
which induces regulated volume increases (RVI). C. 3 proposed mechanisms by which 840 
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